Acute graft versus host disease in liver

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
3 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
HDAC inhibitor 1 substance
Kinase inhibitor 1 substance
Unknown / small molecule 1 substance
Phase IV: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase IV

1 trial
  • Novartis Pharma Services AG Commercial
    PANOBINOSTAT; RUXOLITINIB; SIREMADLIN
    2024-515283-31-00 4 countries 2015 n=33 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma Services AG Commercial 1 Phase IV 0
← All indication landscapes